Study confirms FlowOx™ cost effectiveness and improved quality of life

A newly published health economic study confirms that FlowOx™ therapy in combination with nominal care appears to improve the health-related quality of life (QoL) of patients when compared with standard care and may also be cost saving for payors (NHS). The results therefore indicate that FlowOx™ therapy may be an economically viable treatment.

Horizon 2020 Fast Track

This paper presents independent research funded by the European Commission, through the Horizon 2020 Fast Track to Innovation funding scheme, published in PLOS ONE on January 14th, 2021. (https://doi.org/10.1371/journal.pone.0244851)

This is the first health economy study published on FlowOx and we are excited about the results.

Critical limb ischemia is a severe stage of lower limb peripheral artery disease which can lead to tissue loss, gangrene, amputation and death. FlowOx™ therapy is a novel negative-pressure chamber system intended for home use to increase blood flow, reduce pain and improve wound healing for patients with peripheral artery disease and critical limb ischemia.

Key Conclusions:

  • Improved Quality of Life

FlowOx™ therapy patients gained 0.27 additional quality adjusted life years compared to standard care patients. This equated to a dominant incremental cost-effectiveness ratio per QALY gained.

At the NICE threshold WTP of £20,000 and £30,000 per QALY gained, FlowOx™ therapy in addition to standard care had a 0.80 and 1.00 probability of being cost-effectiveness respectively.

  • Cost effective treatment for Peripheral Artery Disease.

FlowOx™ therapy delivered as a single annual dose may be a cost-effective treatment for peripheral artery disease. FlowOx™ therapy improved health outcomes and reduced treatment costs in this modelled cohort.

Andreas Mollatt is Managing Director of Otivio.

“This is the first health economy study published on FlowOx and we are excited about the results. We see this as an important milestone achieved, but it is a start and we are aware that this study will need to be backed by further research and real life clinical and health economic experience.” Says Andreas Mollatt, CEO of Otivio AS.

Scroll to Top